AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn's Disease – 35.8% Achieved Endoscopic Remission
CompanyDrug

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn’s Disease – 35.8% Achieved Endoscopic Remission

AbbVie Inc. (NYSE: ABBV) announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI (risankizumab‑rzaa) in adults with moderately to severely active…

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children
CompanyDrug

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn's Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success
CompanyDrug

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn’s Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success

NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030
Policy / Regulatory

NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030

Hengrui Wins NMPA Clinical Trial Approval for SHR‑3201 – First‑in‑Class Investigational Therapy Targeting Alzheimer's Disease
CompanyDrug

Hengrui Wins NMPA Clinical Trial Approval for SHR‑3201 – First‑in‑Class Investigational Therapy Targeting Alzheimer’s Disease

- Advertisement -
Ad image
Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth
Company

Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
CompanyDeals

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

EC Approves Gilead's Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk
CompanyDrug

EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk

CompanyDeals

Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones

GSK's Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027
CompanyDrug

GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027

CompanyLegal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

HospitalPolicy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
CompanyDeals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

CompanyDrug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

CompanyDrug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Show More